HLA TYPING USING PCR AMPLIFICATION AND IMMOBILIZED PROBE

Information

  • Research Project
  • 3366403
  • ApplicationId
    3366403
  • Core Project Number
    R01HL047170
  • Full Project Number
    7R01HL047170-02
  • Serial Number
    47170
  • FOA Number
    RFA-HL-90-4B
  • Sub Project Id
  • Project Start Date
    8/1/1991 - 33 years ago
  • Project End Date
    5/31/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1992 - 32 years ago
  • Budget End Date
    5/31/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/30/1992 - 32 years ago
Organizations

HLA TYPING USING PCR AMPLIFICATION AND IMMOBILIZED PROBE

The overall objective of this project is the development of a simple, rapid, and precise method of typing the polymorphism at the HLA class II (in particular, DRB1, DQB1, DPB1, and DQA1) and the class I (HLA-A, B, and C) loci using the polymerase chain reaction (PCR) method of DNA amplification. Our experimental strategy is to use, when possible, locus specific PCR primers and a panel of sequence specific oligonucleotide probes. Our goal is to develop a simple and convenient "reverse dot blot" assay for each locus which involves the hybridization of a labeled PCR product to a strip containing a defined array of immobilized probes in a single reaction, as well as an automated approach to "reading" the genotype from the pattern of probe reactivity. This project will involve the sequence analysis of class I and class II genes from non-Caucasian populations and families to identify new alleles and haplotypes as well as the determination of allele, phenotype, and genotype frequencies in various human populations using oligonucleotide typing. Unlike immunological approaches or RFLP analysis, methods for detecting coding sequence polymorphisin, such as oligonucleotide typing, are valuable because they indicate where and how alleles differ. Individual residues are known to elicit allogeneic T cell responses; consequently, this typing approach should prove valuable for transplantation. In particular, it should help us determine the nature and location of mismatches which are important in determining the clinical outcome of bone marrow transplants. In addition, these assays will continue to help us identify specific class II polymorphic residues which may be implicated in disease susceptibility. They should also prove valuable for studies of peptide, MHC, and T cell receptor interactions.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    7
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SRC
  • Study Section Name
  • Organization Name
    ROCHE MOLECULAR SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ALAMEDA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94501
  • Organization District
    UNITED STATES